Introduction {#Sec1}
============

Recent US guidelines call for all individuals with HIV infection to initiate antiretroviral therapy (Thompson et al. [@CR32]) (ART) upon diagnosis, with prevention of central nervous system (CNS) sequelae serving as one argument for early initiation (Ellis et al. [@CR13]). Despite ART having diminished the most severe CNS sequelae of HIV, subtle neurocognitive impairment continues to be a concern even for those on ART (Heaton et al. [@CR19]). A meta-analysis found robust but modest positive effects of ART on HIV-associated cognitive dysfunction in adults (Al-Khindi et al. [@CR3]). However, few studies have focused on individuals earlier in infection; while studies suggest a significant impact of acute HIV infection on the CNS is due to chronic inflammation that is independent of viral replication (Ancuta et al. [@CR4]), it could be argued that control of viral replication by early ART may protect the CNS. Furthermore, late adolescents and young adults (hereafter referred to as "youth") have received less focus in studies of ART and neurocognition, despite being a population at high risk for HIV and demonstrating relatively high rates of neurocognitive impairment (Nichols et al. [@CR24]). Reservations regarding ART initiation in youth, including poor adherence resulting in emergence of drug resistant virus and toxicity associated with long-term treatment (Gagliardo et al. [@CR15]; Lee et al. [@CR20]), call for studies demonstrating neurocognitive benefit or at least lack of harm associated with ART in youth.

In 2007, the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) began enrollment for ATN 061, a prospective 3-year randomized clinical trial to study the immunological impact for youth of initiating highly active antiretroviral therapy (HAART) early (CD4+ T cell (CD4) counts \>350 cells/mm^3^) compared to delaying treatment until concurrent treatment guidelines were met. This study also examined the effect of treatment de-intensification to boosted protease inhibitor (PI)-monotherapy among participants who achieved sustained viral suppression. The current study, ATN 071, was a 3-year prospective observational study designed to assess changes in neurocognitive functioning associated with early HAART initiation. The study included ATN 061 participants, additional untreated youth, and a group initiating ART per standard of care (SOC). Analysis of baseline data for ATN 071 demonstrated that 66 % of participants qualified for a diagnosis of HIV-associated neurocognitive disorder (Antinori et al. [@CR5]) (HAND) at baseline, with impairments occurring most commonly in memory and learning, executive functioning, and fine motor speed (Nichols et al. [@CR24]). Significant associations of some neurocognitive measures with CD4 count suggested possible subtle effects of HIV on neurocognition. Presented herein are longitudinal analyses of neurocognitive functioning over 3 years to determine whether ART, timing of ART initiation, and treatment de-intensification were associated with differences in the trajectory of neurocognitive functioning over time in ATN 071 while accounting for adherence and important confounding variables. The findings follow up the cohort described in Nichols et al. [@CR24] and represent the first study of the impact of ART on neurocognitive functioning among a key population affected by the HIV epidemic, late adolescents and emerging adults.

Methods {#Sec2}
=======

Participants {#Sec3}
------------

Youth aged 18--24 years with behaviorally acquired HIV infection were enrolled from 15 ATN and 5 International Maternal Pediatric Adolescent AIDS Clinical Trials sites across the USA and Puerto Rico. At the time of enrollment, the *US Department of Health and Human Services Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents* (Guidelines) recommended starting ART in patients with CD4 cells \<350, in absence of contraindications. Recruitment, participants, and assessment methodology are described in Nichols et al. [@CR24], with essential details repeated herein for convenience. Participants enrolled into four groups. Two groups had CD4 \>350 at baseline: group 1 participants had been randomized to initiate early ART upon enrollment in ATN 061, while group 2 deferred ART until SOC guidelines for ART initiation were met. Group 3 participants met Guidelines for ART initiation with CD4 \<350 at enrollment and started treatment. Group 4 (CD4 \<350 and not initiating ART) was seen only at baseline and not discussed herein. Participants co-enrolled in ATN 061 were required to have HIV-1 RNA viral load (VL) \>1000 copies/mm^3^. All participants were treatment-naïve except for ART to prevent mother-to-child HIV transmission (PMTCT; *n* = 3) with total duration of ART \<6 months. Fluency in English or Spanish was required. Exclusion criteria included prior ART experience other than for PMTCT, current pregnancy, active substance use judged likely to interfere with meeting study requirements, psychosis, or significant non-HIV-related cognitive or motor impairment (e.g., cerebral palsy, severe traumatic brain injury; milder comorbidities including learning disabilities and attention-deficit/hyperactivity disorder were allowed). Participants who became pregnant while on study were discontinued due to potential impact of pregnancy on treatment considerations and cognition. The study was approved by Institutional Review Boards at all participating institutions; participants provided written informed consent in accordance with institutional requirements prior to enrollment.

Study evaluations {#Sec4}
-----------------

### Neurocognitive and behavioral functioning {#FPar1}

Study design and evaluations are described elsewhere (Nichols et al. [@CR24]). Participants were followed for 144 weeks, completing study evaluations at baseline and weeks 24, 48, 96, and 144.

The assessment battery included domains with previously demonstrated sensitivity to HAND in adults (Table [1](#Tab1){ref-type="table"}), including memory, motor skills, attention, and complex executive functions. Standard scores using published normative data, with adjustments for age and, where available, race, Hispanic ethnicity, education and/or gender, were computed. Scores within domains were converted to *z*-scores and averaged for analytic clarity and to reduce the number of regression analyses performed. Neurocognitive measures were grouped into two sets: a monitoring battery conducted at all time points and a second set of measures administered only at baseline and exit (Table [1](#Tab1){ref-type="table"}). Analyses reported herein focus on three scales derived from the monitoring battery reflecting attention, motor functioning, and complex executive functioning; individual tests were combined into domain scores to reduce the number of analyses required (Nichols et al. [@CR24]). The domains included in the monitoring battery were selected based on anticipated sensitivity to change (Al-Khindi et al. [@CR3]).Table 1Neurocognitive domains and assessment instrumentsDomain of functioningTest NameMeasure used in analysesMonitoring battery (entry, wks 24, 48, 96, exit) Attention/working memory scaleDigit Span (WAIS-III; Psychological Corporation [@CR31])Subtest standard score converted to z-scoreLetter-Number Sequencing (WAIS-III)Subtest standard score converted to z-score Motor/psychomotor scaleDigit Symbol (WAIS-III)Subtest standard score converted to z-scoreGrooved Pegboard (Strauss et al. [@CR30])Dominant hand total time z-scoreTimed Gait (Robertson et al. [@CR28])Z-score for average time across 3 trials Complex executive scaleTrailmaking Test (Part B; Reitan and Wolfson [@CR27]; Mitrushina et al. [@CR23])Total completion time z-scoreControlled Oral Word Association (Strauss et al. [@CR30])F, A, S & Animals total correct z-scoreStroop Test (Interference trial; Norman et al. [@CR25]; Golden and Freshwater [@CR17])Interference trial z-score Emotional/behavioral covariatesBeck Depression Inventory-II (Beck et al. [@CR6])Total scoreBrief Symptom Inventory (Derogatis [@CR11])Global Severity IndexAlcohol, Smoking and Substance Involvement Screening Test (World Health Organization [@CR35])Risk index for alcohol, marijuana, and other drugsAdherence7-day self-report of percent doses takenEntry and Exit only Global functioningWAIS-III 5-subtest IQ estimatePro-rated IQ estimate derived from Vocabulary, Similarities, Block Design, Arithmetic, Matrix Reasoning subtest Scaled Scores Learning and MemoryHopkins Verbal Learning Test-R (Norman et al. [@CR25]; Benedict et al. [@CR8])Recognition and Recall corrected T- ScoresBrief Visuospatial Memory Test-R (Norman et al. [@CR25]; Benedict et al. [@CR7])Recognition and Recall corrected T- Scores*WAIS-III* Wechsler Adult Intelligenc Scale-Third Edition

Additional measures of depression, psychiatric distress, substance use, and medication adherence were administered for use as covariates in analyses. In addition, participants were asked whether they use potentially psychoactive substances (street drugs or medications; PPS), and whether they used them on the day of testing.

### Demographics and psychosocial history {#FPar2}

Participants reported birth sex, race, ethnicity, primary language, sexual orientation, employment, school enrollment status, past 30-day income, educational attainment, and educational risk (history of special education or repeating a grade).

### Medical record abstraction {#FPar3}

Comorbid current and past conditions were rated according to potential impact on current cognition as none, mild (e.g., headache, adjustment disorder), moderate (e.g., chronic migraines, major depressive disorder), or severe (e.g., seizure disorder, skull fracture), following published guidelines (Antinori et al. [@CR5]). CD4 and plasma VL values within 4 weeks preceding the visit, CDC classification [@CR1], and date of first positive HIV test were abstracted. Treatment variables included concomitant medications, ART initiation, ART regimen, and, for group 1, de-intensification at ATN061 52-week time point following 24 weeks of sustained viral suppression.

Statistical methods {#Sec5}
-------------------

### Descriptive statistics {#Sec6}

Treatment groups were compared using chi-square tests and *t* tests.

### Modeling {#Sec7}

Hierarchical linear modeling (HLM) using software HLM v7.0 (Raudenbush et al. [@CR26]) was used to analyze the longitudinal neurocognitive scales. All scales (attention, motor, and complex executive) are expressed in *z*-score units with mean = 0. HLM accounts for the dependency in observations when data have a nested, multilevel structure, such as observations repeated at different times for the same study participant. The model also incorporates person-level covariates such as demographic characteristics or baseline clinical values. Included person-level baseline characteristics were group, gender, age, race/ethnicity, language spoken, education risk (special education class or repeated grade), education level, income earned in the past 30 days, CD4 count, time since HIV diagnosis, and viral load. Time-varying covariates included comorbid diagnosis rating; Beck Depression Inventory-2 (Beck et al. [@CR6]) score; Brief Symptom Inventory (Derogatis [@CR11]) score; medications with psychotropic effects; use of alcohol, cannabis, tobacco, or other drugs; and medication adherence (7-day self-report of missed doses). Finally, the model also included terms for status of anti-retroviral treatment (including early ART initiation) and ART de-intensification.

Growth curve modeling investigated whether there was nonlinear change in attention, motor, or complex executive indices over time. Both linear and quadratic time measures were included in the model (weeks and weeks^2^, respectively). Because of limits on the number of parameters that could be estimated with five time points and number of random effects, the linear and quadratic terms for time were estimated over all participants rather than for each individual. The growth curve models allowed for testing of group effects, demographic characteristics, and clinical covariates both as factors affecting overall neurocognitive performance and as interactions affecting changes over time in neurocognitive performance. Robust standard errors were used to account for non-normality (Liang and Zeger [@CR21]). Follow-up analyses examined the effect of including baseline IQ in models to account for cognitive reserve; excluding individuals with severe comorbidities from models; and modeling treatment effects after grouping participants according to ART impact into those who never initiated ART (*n* = 36), those who initiated ART with consistent viral suppression across all subsequent time points (*n* = 56), and those who initiated ART with inconsistent or no viral suppression (*n* = 83).

Results {#Sec8}
=======

Population characteristics {#Sec9}
--------------------------

Among 182 study participants enrolled between April 2008 and July 2010, baseline data were available for 181 participants. Participation dropped from 181 at baseline to 171, 151, 139, and 137 at weeks 24, 48, 96, and 144, respectively. Attrition was significantly higher in group 2 (*p* \< 0.005); the most frequent reason was pregnancy, and participants who discontinued were significantly more likely than those who did not to be female (*p* = 0.006). Some individual test data were eliminated from analyses due to issues with validity (e.g., long fingernails interfering with fine motor performance).

Table [2](#Tab2){ref-type="table"} shows demographic characteristics of study participants at baseline. Mean age was 21.0 years. Participants were predominantly male (80.7 %), non-Hispanic Black/African-American (65.2 %) or Hispanic (22.7 %), self-identified as gay or bisexual (71.2 %), and high school educated or beyond (72.3 %), with 40.8 % currently in school and less than half (42.6 %) employed. Approximately 21.5 % reported having repeated a grade, and 22.7 % had received some form of special education. Nine participants (5 %) reported using a language other than English at home. Of those, one Spanish-speaking participant was tested in Spanish; the remainder, who were bilingual, completed testing in English. Demographic differences between groups are presented in Table [2](#Tab2){ref-type="table"}.Table 2Demographic and baseline dataCharacteristicGroup 1 initiating ART with CD4+ \>350Group 2, CD4+ \>350, not initiating ARTGroup 3 initiating ART with CD4+ \<350Overall*p* valueCount/meanPercent/std. dev.Count/meanPercent/std. dev.Count/meanPercent/std. dev.Count/meanPercent/std. dev.Time point Baseline56100.066100.059100.0181100.00.0020 Week 245292.96395.55694.917194.5 Week 484885.75380.35084.715183.4 Week 964885.74568.24678.013976.8 Week 1444783.94466.74678.013775.7Age (years)20.91.621.21.820.81.921.01.80.5104Male gender4987.54568.25288.114680.70.0051Race/ethnicity0.7933 Hispanic1119.61827.31220.34122.7 Non-Hispanic White47.169.135.1137.2 Non-Hispanic Black/African American3867.93857.64271.211865.2 Asian/Pacific Islander23.623.000.042.2 Other or mixed race11.823.023.452.8Language at home0.4694 English5191.16598.55694.917295.0 Spanish47.111.523.473.9 Other11.800.011.721.1Transgender23.634.546.895.00.7661Sexual orientation0.0233 Straight (heterosexual)1017.92537.91118.64625.4 Gay/lesbian (homosexual)4173.23147.03966.111161.3 Bisexual35.4913.6610.2189.9 Not sure/questioning23.600.011.731.7 Refused to answer00.011.523.431.7Educational status0.6315 Attending school1933.91928.82033.95832.0 GED program58.946.1711.9168.8 Not currently in school3053.64263.63254.210457.5 Other23.611.500.031.7Level of education0.8382 Eighth grade or less23.611.523.452.8 Not completed high school1628.61725.81220.34524.9 High school graduate1323.21725.82135.65128.2 Some education after high school2341.12639.42135.67038.7 College graduate23.657.635.1105.5Repeated a grade1425.01015.21525.43921.50.3041Special class or education1832.1812.11525.44122.70.0283Current employment0.0098 Full-time1425.02233.3711.94323.8 Part-time58.91319.71627.13418.8 Not employed3664.33147.03661.010356.9 Refused to answer11.800.000.010.6Past year income0.4411 \<\$60003969.63857.64474.612166.9 \$6000--\$35,9991526.82537.91525.45530.4 Refused to answer11.811.500.021.1 Unknown11.823.000.031.7Potential impact of comorbid diagnoses Severe35.446.135.1105.50.9894 Moderate1730.42436.42033.95933.7 Mild58.9710.6610.21610.0 None3155.33146.93050.88950.8

Clinical HIV characteristics {#Sec10}
----------------------------

According to reported dates for first positive HIV test, approximately half the sample had been diagnosed with HIV for less than a year (Table [3](#Tab3){ref-type="table"}; see Agwu et al. [@CR2] for discussion of length of infection in associated ATN 061). Significantly fewer participants in group 2 (7.6 %) had been diagnosed less than 4 months prior to baseline compared with group 1 (25.0 %) or group 3 (35.6 %) (*p* = 0.0024). Youth with CD4 counts [\>]{.ul}350 at baseline accounted for 94.6 % of group 1, 98.5 % of group 2, and 6.8 % of group 3; inclusion of participants in groups 1 and 2 with CD4 count \<350 was due to changes in CD4 between eligibility screening and baseline assessments. Almost 90 % overall were in CDC category A, and all but 1.7 % had VL above 400 copies at baseline; 10.2 % of group 3 had AIDS by CD4 count \<200 at baseline. Baseline VL distribution differed across the three groups, with 10.7 % of group 1 participants having VL above 100,000 copies vs. 3.0 % for group 2 and 17.6 % for group 3 (*p* \< 0.005). ARV regimens were provider selected except for group 1, who initiated atazanavir/ritonavir plus tenofovir/emtricitabine as part of ATN 061. Regimens prescribed for group 3, as well as the subset of group 2 who subsequently initiated treatment per guidelines, were standard combinations of protease inhibitors (PI), nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), and integrase inhibitors (II). Altogether, 104 study participants used PI-based regimens during most or all of study duration, 34 were on NNRTIs, 2 were on II regimens, and 1 each were on NNRTI/II and PI/II regimens. Thirty-three participants used regimens containing efavirenz for most or all of study duration; an additional four used an efavirenz-containing regimen for part of their time on study. Reported adherence averaged 85 to 90 % over the course of the study (data not shown). There was a pronounced effect of treatment on both VL and CD4 counts, with VL decreasing and CD4 counts increasing between entry and week 144 for youth who initiated treatment (Table [3](#Tab3){ref-type="table"}). Of group 1 participants, 35 underwent treatment de-intensification at week 48 to atazanavir/ritonavir monotherapy.Table 3Clinical data at baseline and end of studyCharacteristicGroup 1 \>350; starting ARTGroup 2 \>350; ART monitored per SOCGroup 3 \<350; starting ART per SOCOverall*p* valueCount/meanPercent/std. dev.Count/meanPercent/std. dev.Count/meanPercent/std. dev.Count/meanPercent/std. dev.Time since HIV diagnosis at entry (months)0.0024 \<41425.057.62135.64022.1 4--111832.11725.81932.25429.8 12--261323.22131.8813.64223.2 ≥271119.62334.81118.64524.9CDC classification for HIV at entry0.0564 A5191.16395.54881.416289.5 B58.934.51016.9189.9 C00.000.011.710.6Viral loadAt study entry \<40000.023.011.731.70.0049 400 to 10,0001730.43654.51525.46837.6 10,001 to 100,0003358.92639.43254.29150.3 100,001 to 500,00058.923.01016.9179.4 \>500,00011.800.011.721.1Mean (std. dev.)4.30.53.90.64.40.74.20.60.0001Median (range)4.23.3--6.13.92.5--5.14.42.6--5.94.22.5--6.1At end of study \<4003268.12045.53678.38864.20.0117 400 to 10,000919.11227.336.52417.5 10,001 to 100,000612.81022.7715.22316.8 100,001 to 500,0000024.50021.5 \>500,00000000000.0Meanlog~10~ units (std. dev.)3.11.13.81.03.90.93.61.00.0631Median (range)3.41.4--4.73.91.6--5.74.22.1--5.04.01.4--5.7CD4+ countAt study entry \<20000.000.0610.263.3\<0.0001 200 to 34935.411.54983.15329.3 350 to 4992442.92639.446.85429.8 ≥5002951.83959.100.06837.6Mean (std. dev.)552.4188.4595.6200.6275.779.0478.0218.1\<0.0001Median (range)506.5280--1167533.0300--1160288.016--498440.016--1167At end of study \<20000.036.80032.20.0025 200 to 34936.449.1919.61611.7 350 to 49924.3511.4919.61611.7 ≥5004289.43170.52554.39871.5Mean (std. dev.)808.8278.6584.5225.5556.1212.6654.6266.20.0168Median (range)789.0227--1476604.080--1076536.0205--1067651.080--1476CD4+ percentAt study entry \<15 %35.400.01830.52111.6\<0.0001 15 to 24 %1730.42334.83762.77742.5 \>24 %3664.34365.246.88345.9Mean (std. dev.)27.27.128.38.217.56.223.88.7\<0.0001Median (range)28.413--4028.115--5018.01--3423.81--50At end of study \<15 %48.5511.424.3118.00.4513 15 to 24 %24.349.1613128.8 \>24 %4187.23477.33576.111080.3Mean (std. dev.)35.510.330.711.431.49.032.610.40.0168Median (range)38.010--5332.00.3--5231.07.5--5034.00.3--53.0

Neurocognitive measures over time by group {#Sec11}
------------------------------------------

Figure [1a--c](#Fig1){ref-type="fig"} shows descriptive statistics by group for the three neurocognitive scales over time.Fig. 1Descriptive statistics by group for **a** attention, **b** motor, and **c** complex executive scales over time

Hierarchical linear modeling {#Sec12}
----------------------------

Table [4](#Tab4){ref-type="table"} shows the results of fitting hierarchical linear models to the attention, motor, and complex executive scales. All models contain terms for demographic and clinical covariates, as well as for change over time.Table 4Hierarchical linear model for attention, motor and complex executive scalesHLM termsCoefficientStd. error*p* valueAttention scaleModel for baseline intercept Intercept0.1610.1750.358 Hispanic (vs. non-Hispanic white and other)−0.4120.1930.034 Non-Hispanic Black (vs. non-Hispanic white and other)−0.3490.1780.052 Education risk (special class or repeated grade)−0.4270.106\<.001Model for change over time Linear term0.0830.023\<.001 Quadratic term−0.0110.0040.005Effect of diagnoses with severe potential impact Intercept−0.2340.1190.051 Baseline viral load0.5430.144\<.001Effect of diagnoses with moderate potential impact Intercept0.0970.0530.072 Baseline viral load0.0800.0490.102Motor ScaleModel for baseline intercept Intercept−1.0450.153\<.001 Male gender0.4810.1680.005Model for change over time Linear term0.3040.027\<.001 Quadratic term−0.0370.004\<.001Effect of diagnoses with severe potential impact Intercept−1.6700.195\<.001 Male gender1.2570.243\<.001Effect of diagnoses with moderate potential impact Intercept−0.4740.2440.053 Male gender0.4400.2590.092Complex executive scaleModel for baseline intercept Intercept0.1790.1270.161 Age−0.0810.0330.016 Hispanic (vs. non-Hispanic White and other)−0.5750.138\<.001 Non-Hispanic Black (vs. non-Hispanic White and other)−0.4720.126\<.001 Education risk (special class or repeated grade)−0.3490.096\<.001Model for change over time Linear term0.0890.025\<.001 Quadratic term−0.0140.0040.001Effect of diagnoses with severe potential impact Intercept−1.6400.119\<.001 Age0.0740.0390.061 Male gender1.5290.121\<.001 CD4 at baseline0.1540.021\<.001 Viral load at baseline0.7020.068\<.001Effect of diagnoses with moderate potential impact Intercept−0.2270.1480.127 Age−0.1350.035\<.001 Male gender0.3770.1600.020 CD4 at baseline0.0330.0240.177 Viral load at baseline−0.0140.0660.835

### Attention index {#FPar4}

The attention index, adjusted for covariates, increased from 0.161 at baseline to 0.317 at week 96, and then decreased slightly to 0.263 by week 144. Significantly lower attention index at baseline was seen in youth who were Hispanic, had education risk, or had comorbid diagnoses with potentially severe neurocognitive impact (e.g., seizure disorder). Other covariates (see "[Methods](#Sec2){ref-type="sec"}" section) were not significantly associated with the attention scale. Covariates did not interact significantly with the attention index over time.

### Motor index {#FPar5}

The motor index increased from −1.045 at baseline to −0.421 at week 96 and then decreased slightly to −0.553 by week 144. Male youth had significantly better motor performance than females. Youth with comorbid diagnoses with potentially severe or moderate neurocognitive impact had significantly lower mean baseline motor index than those with mild or no diagnoses. Other covariates were not significantly associated with the motor scale.

### Complex executive index {#FPar6}

The complex executive index increased from 0.179 at baseline to 0.311 at week 96 and then decreased to 0.209 by week 144. Baseline executive index was significantly lower for participants who were older, Hispanic and non-Hispanic Black (vs. non-Hispanic White/other), had education risk, or had severe potential impact of diagnoses. Other covariates were not significantly associated with the complex executive scale.

Notably, there were no significant differences between study groups at baseline or in changes over time in the attention index, motor index, or executive index. Similarly, there were no observed differences in any index for participants who de-intensified their ARV medication. Relationships between covariates and index scores differed by comorbid diagnosis impact but did not interact with treatment (Table [4](#Tab4){ref-type="table"}). Follow-up analyses showed that including baseline IQ as a covariate, excluding individuals with severe comorbidities, or grouping participants according to virologic response to ART did not cause a significant treatment effect on index scores to emerge. Higher full-scale IQ at baseline was associated with higher index scores at baseline and greater improvement in motor/psychomotor index scores over time, but the inclusion of IQ in models of group effects did not alter treatment findings.

Discussion {#Sec13}
==========

This paper reports findings from the first prospective observational study of neurocognitive functioning in YLWH initiating ART at different CD4 thresholds. Models of trajectories of neurocognitive functioning over 3 years were examined for both positive and negative change. A broad neurocognitive, behavioral, demographic, and health history database allowed for the evaluation of several cognitive domains and multiple potential confounding factors. The key finding is that all three cognitive functional domains considered here improved significantly over time, each peaking at about 96 weeks into the study. Some degree of positive change was anticipated due to the likelihood of practice effects for neurocognitive measures (Duff [@CR12]; Woods et al. [@CR34]); our analytic approach was designed to compare the magnitude of change across groups. However, while there were modifying effects of demographic characteristics and non-HIV medical diagnoses, the magnitude and direction of change were not associated with treatment group or with clinical indicators of HIV-related disease factors. In addition, there were no differences associated with treatment de-intensification following viral suppression among early-treated youth, supporting safety of this management approach.

Prior studies with adults have found that ART is associated with modest improvements in cognitive functioning overall and that these improvements are seen largely in the areas of attentional, motor, and executive functioning (Al-Khindi et al. [@CR3]). The sensitivity of these functional domains to HIV as well as to ART was the reason they were chosen for longitudinal monitoring in youth in the study reported here. The measures selected were ones that had a well-established track record in the adult HIV literature. The significant associations of the neurocognitive measures with other risk factors for the participants, such as educational risk and comorbid diagnoses, were in the predicted directions, suggesting that the lack of significant treatment effects was not likely due to insensitivity of the measures. Further support for measurement sensitivity comes from baseline findings showing subtle associations of some cognitive variables with CD4 count (Nichols et al. [@CR24]). Nevertheless, treatment effects were not detected for our groups of youth with behaviorally acquired HIV.

There are several possible reasons that we did not observe effects of ART on cognitive functioning. One possibility is that, despite concern raised by the baseline findings regarding HIV impact on the CNS even in our relatively healthy cohort of youth, the contribution of HIV to neurocognitive functioning in our complex cohort is small enough relative to other influences and comorbidities that improvements with ART were too subtle to be detected with our sample size. A second possible explanation is that the medications did not adequately penetrate the central nervous system; a relatively narrow range of penetrance was represented and regimens for the most part were not highly penetrant (data not shown). A third possibility that could be raised is that participants were not adhering to their medications; however, reported adherence was reasonably good overall, supported by changes in CD4 and viral load, adherence was included as a covariate in analyses, and analyzing data according to virologic ART response did not alter the findings. Fourth, it may be that the observed impairments are related to persistent immune activation and inflammation established early in infection that is not reversed by ART (Ancuta et al. [@CR4]; Wallet et al. [@CR33]). Data collected from ATN 061 have demonstrated that T cell activation decreases with treatment but does not approach that of uninfected adolescents. In addition, ATN 061 demonstrated that, even with early initiation of ART, inflammatory markers including sCD14, sCD163, and sCD27 began and remained significantly higher than among a cohort of uninfected comparison youth similar in age, race, and substance use to the ATN 061 cohort (Rudy et al. [@CR29]). An additional possibility is that the impairments seen at baseline were not related to HIV and that the CD4 findings were spurious. Rigorous measures were taken to account for other influences on neurocognitive functioning (Nichols et al. [@CR24]), and exclusion of individuals with the most severe comorbidities did not affect the findings, but it should be acknowledged that controversy exists regarding the specificity of mild, asymptomatic neurocognitive impairments in adults with HIV disease (Gisslen et al. [@CR16]; Grant et al. [@CR18]; McDonnell et al. [@CR22]). Further studies are needed to explore the impact of ART in the context of treatment begun in acute infection, using additional CNS measures such as neuroimaging, to evaluate regimens with a wider range of CNS penetrance, and to examine longitudinal associations with biomarkers of immune activation and inflammation.

With changes in US treatment guidelines, which now recommend ART in all HIV-infected persons regardless of immune function, evaluation of potential neurotoxicity of regimens has assumed greater importance. Particularly for young, asymptomatic individuals facing a lifetime of ART, concern about potential negative impacts of ART on functioning may decrease willingness to initiate or adhere to treatment. It is noteworthy that our findings indicated similar neurocognitive improvement in participants regardless of ART, suggesting lack of a negative impact of ART in general. Exploratory analyses including efavirenz, a medication that has been associated with CNS toxicity (Ciccarelli et al. [@CR9]; Decloedt and Maartens [@CR10]), did not find a differential effect on neurocognitive functioning. However, the number of youth taking this medication was small. Further studies are needed to support the safety of early ART in youth.

As noted in our description of baseline findings from ATN 071 (Nichols et al. [@CR24]), a high percentage of youth in our cohort demonstrated neurocognitive impairment. Important questions remain for future studies, particularly if further studies continue to show that these impairments do not improve with ART. The origin of impairments may include modifiable factors such as substance use that could be the target of preventive interventions. Potential interventions could also include cognitive remediation, lifestyle modification such as exercise, as well as provision of enhanced education for healthcare-related and other daily living tasks for youth with impairment(s). Youth with the most significant impairments may be at risk for poor adherence, potentially leading to cognitive decline as part of disease progression (Ettenhofer et al. [@CR14]); cognitive screening could be used to select youth for more intensive adherence support. The potential impact of impairments on other HIV prevention efforts, such as effectiveness of risk behavior reduction interventions, has public health implications and merits further research. Finally, long-term studies are needed to determine whether YLWH who have cognitive impairments are more vulnerable to cognitive decline associated with other risks such as head injury or aging. Exploratory analyses of our data demonstrated that neurocognitive impairment at baseline was associated with differences in trajectory of change, a finding that will be explored further in subsequent publications; however, it should be noted that inclusion of baseline cognitive performance or HAND diagnosis did not alter the finding of no treatment effects.

This study has several limitations. A primary limitation is that, while a portion of the participants with CD4 \>350 were randomized to treatment or no treatment, the study as a whole was not a randomized clinical trial. In fact, treatment guidelines to initiate ART following HIV diagnosis preclude randomized studies comparing treated and untreated YLWH. Differences between the three study groups in some characteristics other than CD4 at baseline may have contributed to lack of a treatment effect and limit conclusions that can be drawn. However, it should be noted that analyses considered these characteristics as well as other variables. An additional limitation was the lack of an uninfected control group which could address nonspecific effects such as practice and possible developmental changes over time (however, age-standardized scores were used to account for development). Future studies should follow a well-matched uninfected group of youth to help account for these effects. Measurement of nonspecific clinical effects of participation, such as more frequent interaction with the clinic team, may also partially explain the non-ART-related positive change. Measures of memory and learning were included only at baseline and week 144 and were not included in these analyses; however, exploratory analyses demonstrated no associations of treatment with change in these measures. Although a significant number of youth were recently diagnosed with HIV, the study did not focus on youth with acute infection, a group likely to be most impacted by changes in treatment guidelines. Follow-up continued for 3 years, which may not have been protracted enough to observe longer term impacts of HIV and ART in youth. Finally, sample sizes were small for evaluation of some effects such as treatment de-intensification.

In conclusion, despite evidence of significant impairment at baseline, youth with behaviorally acquired HIV showed modest positive changes in neurocognitive functioning over 3 years of follow-up that were not related to antiretroviral treatment. Further research is needed to evaluate the impact of earlier treatment, newer regimens, and those with greater CNS penetrance.

Portions of the research described herein were presented at the network meeting of the Adolescent Trials Network for HIV/AIDS Interventions in Bethesda, Maryland in October, 2014, and at the Conference on Retroviruses and Opportunistic Infections in Seattle, Washington, in February, 2015.
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